949
Views
2
CrossRef citations to date
0
Altmetric
Letter to the Editor

Successful treatment of angioimmunoblastic T-cell lymphoma with the retinoid X receptor agonist, bexarotene

, , , , , & show all
Pages 1815-1817 | Received 25 Feb 2011, Accepted 07 Apr 2011, Published online: 17 May 2011

Figures & data

Figure 1.  (A) Image from December 2001 biopsy: The nodal architecture is effaced by a polymorphic cellular infiltrate, with a spectrum of lymphoid cells (including clusters of clear cells and scattered large atypical immunoblasts), as well as eosinophils and prominent vascular elements, with frequent arborizing vessels. Hematoxylin and eosin, original magnification ×200. (B) EBV PCR on peripheral blood. Both peripheral whole blood (WB) and plasma (P) were subjected to EBV quantitative real-time PCR utilizing primer sets against EBV encoded RNA (EBER) and EBNA on days 0, 7, 14, and 28 of bexarotene (Viracor-IBT Laboratories, Lee’s Summit, MO).

Figure 1.  (A) Image from December 2001 biopsy: The nodal architecture is effaced by a polymorphic cellular infiltrate, with a spectrum of lymphoid cells (including clusters of clear cells and scattered large atypical immunoblasts), as well as eosinophils and prominent vascular elements, with frequent arborizing vessels. Hematoxylin and eosin, original magnification ×200. (B) EBV PCR on peripheral blood. Both peripheral whole blood (WB) and plasma (P) were subjected to EBV quantitative real-time PCR utilizing primer sets against EBV encoded RNA (EBER) and EBNA on days 0, 7, 14, and 28 of bexarotene (Viracor-IBT Laboratories, Lee’s Summit, MO).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.